How to buy Incyte Corporation (INCY:NASDAQ) stocks in Canada

realTimeClose: - changeP: N/A

Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $65.17 – a decrease of 0.64% over the previous day. Incyte Corporation employs 2,524 staff and has a trailing 12-month revenue of around $3.9 billion.

How to buy shares in Incyte Corporation

Open a brokerage account. Choose from our top broker picks or compare brokers in depth. Then, complete an application.
Fund your account. Add money to your account via bank transfer, debit card or credit card.
Search the platform by ticker symbol. INCY in this case.
Choose an order type. Place a market order or limit order with your preferred number of shares or dollar amount.
Submit the order. It's that simple.

The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Go to site

Easy to use app

100 free trades signup offer
Easy-to-use platform
Low fees
Student and young investor discounts

Go to site

Low margin rates

Access to international stock exchanges
Low margin rates
Powerful research tools

Go to site

CA & US trading

6% cash rebate plus $2,200 in trading perks
Low transaction fees
Easy-to-use app

Our selection of top picks is based on the same criteria as our annual Stock Trading Platform Awards. This is updated yearly to reflect changes in the market.

"Best for" picks are those we've evaluated to be best for specific product features or categories – you can read our full methodology here. If we show a "Promoted" pick, it's been chosen from among our commercial partners and is based on factors that include special features or offers, and the commission we receive.

This isn't an exhaustive list of all the trading platforms out there. What's best for you depends on your own investing strategy, budget and financial goals.

Is Incyte Corporation under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Incyte Corporation P/E ratio, PEG ratio and EBITDA.

Incyte Corporation's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 159x. In other words, Incyte Corporation's stocks trade at around 159x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5445. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $124.2 million ($1 CAD).

The EBITDA is a measure of Incyte Corporation's overall financial performance and is widely used to measure a its profitability.

Frequently asked questions

Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
It's as easy to sell Incyte Corporation as it is to buy! Here's how to sell Incyte Corporation stocks that you already own.
1. Open your investment app. If you've got one with desktop access, you can log in online
2. Go to your portfolio. This should be in the main menu
3. Find your shares. You may be able to search your portfolio
4. Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
5. Sell your Incyte Corporation shares. Your investment platform will let you know when your shares are sold

Incyte Corporation financials

Revenue TTM	$4.1 billion
Operating margin TTM	14.96%
Gross profit TTM	$1.6 billion
Return on assets TTM	-0.12%
Return on equity TTM	0.8%
Profit margin	0.8%
Book value	$16.45
Market capitalisation	$15 billion

TTM: trailing 12 months

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.